Timing, Fundamentals, and Diversification of Dynavax Technologies Corporation (DVAX)

Dynavax Technologies Corporation (NASDAQ: DVAX) closed the day trading at 10.07 down -2.89% from the previous closing price of $10.37. In other words, the price has decreased by $-0.30 from its previous closing price. On the day, 1763512 shares were traded. DVAX reached its highest trading level at $10.49 during the session, while it also had its lowest trading level at $10.07.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .



For a better understanding of DVAX, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.49 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 9.07. For the most recent quarter (mrq), Quick Ratio is recorded 2.60 and its Current Ratio is at 2.80. In the meantime, Its Debt-to-Equity ratio is 0.52 whereas as Long-Term Debt/Eq ratio is at 0.52.

Upgrades & Downgrades

On August 06, 2021, Goldman started tracking the stock assigning a Buy rating and target price of $19.

H.C. Wainwright reiterated its Buy rating for the stock on August 07, 2020, while the target price for the stock was revised from $14 to $12.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 15 when Hack Andrew A. F. sold 3,000,000 shares for $14.68 per share. The transaction valued at 44,040,000 led to the insider holds 5,415,000 shares of the business.

Janssen Robert sold 7,938 shares of DVAX for $134,277 on Aug 09. The Senior Vice President now owns 35,519 shares after completing the transaction at $16.92 per share. On Aug 09, another insider, Novack David F, who serves as the President & COO of the company, sold 26,250 shares for $16.92 each. As a result, the insider received 444,037 and left with 53,213 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DVAX now has a Market Capitalization of 1.31B and an Enterprise Value of 1.05B. As of this moment, Dynavax’s Price-to-Earnings (P/E) ratio for their current fiscal year is 7.51. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.91 while its Price-to-Book (P/B) ratio in mrq is 3.01. Its current Enterprise Value per Revenue stands at 1.56 whereas that against EBITDA is 4.24.

Stock Price History:

The Beta on a monthly basis for DVAX is 1.34, which has changed by -48.62% over the last 52 weeks, in comparison to a change of -14.81% over the same period for the S&P500. Over the past 52 weeks, DVAX has reached a high of $21.39, while it has fallen to a 52-week low of $7.26. The 50-Day Moving Average of the stock is 13.25, while the 200-Day Moving Average is calculated to be 12.21.

Shares Statistics:

Over the past 3-months, DVAX traded about 2.05M shares per day on average, while over the past 10 days, DVAX traded about 2.02M shares per day. A total of 126.35M shares are outstanding, with a floating share count of 126.11M. Insiders hold about 0.20% of the company’s shares, while institutions hold 95.30% stake in the company. Shares short for DVAX as of Aug 30, 2022 were 15.69M with a Short Ratio of 7.64, compared to 17.99M on Jul 28, 2022. Therefore, it implies a Short% of Shares Outstanding of 12.40% and a Short% of Float of 15.68%.

Earnings Estimates

Current recommendations for the stock of the company come from 3 analysts. On average, analysts expect EPS of $0.22 for the current quarter, with a high estimate of $0.23 and a low estimate of $0.21, while EPS last year was $0.02. The consensus estimate for the next quarter is $0.3, with high estimates of $0.31 and low estimates of $0.29.

Analysts are recommending an EPS of between $1.2 and $1 for the fiscal current year, implying an average EPS of $1.11. EPS for the following year is $0.7, with 4 analysts recommending between $2.71 and $-0.91.

Revenue Estimates

4 analysts predict $150.99M in revenue for the current quarter. It ranges from a high estimate of $160.34M to a low estimate of $146.68M. As of the current estimate, Dynavax Technologies Corporation’s year-ago sales were $41.59M, an estimated increase of 263.00% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $173.43M, an increase of 60.20% less than the figure of $263.00% in the same quarter last year. There is a high estimate of $181.5M for the next quarter, whereas the lowest estimate is $165.56M.

A total of 4 analysts have provided revenue estimates for DVAX’s current fiscal year. The highest revenue estimate was $656.69M, while the lowest revenue estimate was $611.72M, resulting in an average revenue estimate of $643.58M. In the same quarter a year ago, actual revenue was $439.44M, up 46.50% from the average estimate. Based on 4 analysts’ estimates, the company’s revenue will be $505.12M in the next fiscal year. The high estimate is $865.6M and the low estimate is $139.78M. The average revenue growth estimate for next year is down -21.50% from the average revenue estimate for this year.